✦ LIBER ✦

7123 First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): an update on overall survival

✍ Scribed by Melichar, B.; Bracarda, S.; Bellmunt, J.; Ravaud, A.; Negrier, S.; Jethwa, S.; Escudier, B.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN16 COST OF MANAGING SIDE EFFECTS OF F

✍ GH Mickisch; B Escudier; M Gore; S Walzer; MJ Nuijten 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB

4518 POSTER First-line bevacizumab impro

✍ Melichar, B.; Koralewski, P.; Pluzanska, A.; Ravaud, A.; Bracarda, S.; Szczylik, 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 67 KB

4008 POSTER Bevacizumab/interferon-alpha

✍ S. Bracarda; P. Koralewski; A. Pluzanska; A. Ravaud; C. Szczylik; C. Chevreau; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 85 KB

7126 What is the impact of subsequent an

✍ Bracarda, S.; Bellmunt, J.; Negrier, S.N.; Melichar, B.; Ravaud, A.; Jethwa, S.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

PCN17 COST OF MANAGING SIDE EFFECTS OF F

✍ GH Mickisch; B Escudier; M Gore; G Procopio; S Walzer; MJ Nuijten 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

94 A REAL-LIFE COMPARATIVE EFFECTIVENESS

✍ G.H. Mickisch; B. Schwander; B. Escudier; J. Bellmunt; J.P. Maroto; C. Porta; S. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 87 KB